Corona drug could be approved this year
The Braunschweig-based start-up Corat Therapeutics is currently testing its drug on patients. If all goes well, the company plans to apply for emergency approval before the end of the year.
Biopharma start-up Corat Therapeutics hopes to submit an application for provisional approval for a drug to treat Covid 19 disease later this year. The current development could lead to an application for emergency approval at the end of the year, the company's chief scientific officer, André Frenzel, told Deutsche Presse Agentur.
At the end of April, the Braunschweig-based start-up announced that it was testing its drug COR-101 on sufferers in a clinical trial. The drug consists of monoclonal antibodies designed to help moderate and severe sufferers. 45 patients in five German cities are testing COR-101. "COR-101 is intended to be used to treat adult patients who have to be hospitalised because of COVID-19 and who may already require oxygen," said Helmut Salih, a physician from Tübingen and head of the study. "We are very confident that this study will be successful." The first results should be known in the summer.
Corat Therapeutics was founded in April 2020 as a spin-off of the biotech company Yumab with the aim of developing a corona drug. The company is financially supported by the Lower Saxony State Bank and private investors.
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.LinkedIn Connect
FYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?